Eradivir, a clinical-stage biotechnology company developing small-molecule immunotherapies that harness the body’s immune system to combat viral infections, announced the closing of a $10 million private financing round.
The new funding will accelerate ongoing clinical and preclinical programs, including the continued development of its lead antiviral therapeutic for influenza, EV25, and advancement of EV148, a potential therapy for respiratory syncytial virus (RSV).
A substantial portion of the $10 million financing came from existing investors, reflecting strong confidence in Eradivir’s scientific platform and leadership. The company’s strategy of raising milestone-based tranches totaling $30 million has allowed it to minimize dilution while maintaining consistent progress toward key clinical milestones.
The latest funds have been directed toward the completion of Eradivir’s EV25 Phase 2a influenza challenge study, which evaluates the efficacy and tolerability of the company’s lead compound. The company plans to release the study results publicly in the coming weeks. Additionally, this financing supports IND-enabling studies for EV148, its RSV candidate, positioning Eradivir for further pipeline growth.
Both EV25 and EV148 are derived from Eradivir’s proprietary BAiT (Bispecific Antigenic immuno-Therapy) platform—a breakthrough approach that merges the precision of antibodies with the simplicity and scalability of small molecules. By swapping the targeting ligand on its bispecific framework, the BAiT platform can be rapidly adapted to target various disease-causing cells, enabling applications beyond viral infections, including oncology.
The company’s pipeline represents a growing class of immunotherapies designed to bridge the gap between traditional antibody therapeutics and next-generation small molecule drugs, offering the potential for broad impact in infectious disease treatment.
KEY QUOTE:
“The funding marks a pivotal moment for Eradivir as we prepare to share EV25 Phase 2a results and underscores the confidence investors have in our ability to build out our toolkit of small molecule immunotherapies. We’ve minimized dilution by raising our first $30 million in milestone-based tranches. This disciplined financing strategy has preserved shareholder value while driving meaningful progress in our lead programs.”
Martin Low, Chief Executive Officer, Eradivir
